The median age of patients diagnosed with advanced non–small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented ...
Feb 22, 2013
0
0
Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments, according to new research published in the cancer journal Annals ...
Jan 9, 2013
0
0
German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
Dec 19, 2012
0
0
(Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients with metastatic ...
Nov 14, 2012
0
0
A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce a particular kind of brain tumor in patients with tuberous sclerosis complex (TSC)—a genetic disease ...
Nov 13, 2012
0
0
(Medical Xpress)—Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their ...
Nov 12, 2012
0
0
A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' ...
Oct 31, 2012
0
0
Cannabis seems to ease the painful muscle stiffness typical of multiple sclerosis, indicate phase III trial results, published in the Journal of Neurology Neurosurgery and Psychiatry.
Oct 9, 2012
0
0
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Oct 1, 2012
0
0
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 ...
Sep 30, 2012
0
0
